Market Overview

Illumina Creates Helix: Here's What It Is, And What It's Worth

Illumina Creates Helix: Here's What It Is, And What It's Worth

The New York Times on Tuesday discussed the creation of Helix, a new gene sequencing venture. The creation of the new company has the backing and support of Illumina, Inc. (NASDAQ: ILMN), along with the investment firms Warburg Pincus and Sutter Hill Ventures.

According to the publication, the creation of Helix is "meant to help support the genetic analysis ecosystem" and will use Illumina's existing technology to "sequence customers' genetic information, and then place that data in the cloud and make it available to partners."

Mizuho: Helix A ‘Long-Term Play' On Consumer Genomics'

Peter Lawson of Mizuho Securities commented in a note on Tuesday that Helix represents a "long-term play" on consumer genomics and signals Illumina's commitment towards driving growth in the end-market outside of basic research.

"We see the creation of Helix dovetailing with the Illumina Accelerator, establishing an ecosystem and locking in future customers," Lawson wrote. "We estimate Illumina's current market opportunity for consumer genomics is relatively small ($100-$200 million), but with substantial long-term upside."

Lawson said Helix could capture a greater share of the expanding market by providing a "robust platform" to both industry and end-user consumers. The analyst added that most of the consumer base right now is focused on arrays, so pushing the uptake of sequencing would be a "key and attainable goal."

The analyst also noted that the company will consolidate Helix in its financial statements, with the pro-rata impact attributable to outside investors reflected in a non-controlling interest line item in the income statement.

Finally, the announcement isn't expected to impact Illumina's 2015 guidance and will be approximately $0.10 dilutive to 2016 earnings.

Lawson maintained a Buy rating on shares of Illumina with a price target raised to $250 from a previous $240.

Latest Ratings for ILMN

Oct 2019MaintainsHold
Oct 2019MaintainsOverweight
Oct 2019Initiates Coverage OnBuy

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: Gene Sequencing Helix Illumina AcceleratorAnalyst Color Health Care Price Target Analyst Ratings General Best of Benzinga


Related Articles (ILMN)

View Comments and Join the Discussion!

Latest Ratings

WEEDMKM PartnersMaintains30.0
NKTRH.C. WainwrightMaintains32.0
GOODNational SecuritiesInitiates Coverage On25.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Economic Data Release Presents Trade Opportunity

Morning Market Gainers